China’s Junshi prices domestic anti-PD-1 mAb at deep discount

Shanghai Junshi Biosciences Co. Ltd. (HKSE:1877) priced its domestically developed anti-PD-1 mAb Tuoyi toripalimab at a deep discount compared with the China price of Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK), which has the same mechanism.

Junshi set Tuoyi’s price at RMB7,200 ($1,050.91) per 240 mg. On a per-milligram basis, the price is an 83% discount compared with Keytruda's RMB17,918 ($2,615.31) per 100 mg. Both drugs are approved in China to treat melanoma (see "China Approves First Anti-PD-1 for Melanoma"). ...